Protective effects and mechanisms of polyethylene glycol loxenatide against hyperglycemia and liver injury in db/db diabetic mice
The SELECT study: a warning In 2023, semaglutide was shown to reduce the rates of major adverse cardiovascular events by 20% among persons with a history of atherosclerotic cardiovascular disease and obesity or in persons with overweight and one or more weight-related complications [79]
And importantly, it interacts with the part of the brain that processes reward
CLINICAL TRIAL EVIDENCE FOR GLP-1 RAs IN MASH Table 2 provides a summary of phase 2 and phase 3 studies examining GLP-1 RAs and dual or triple agonists (aiming glucagon, GIP, and GLP-1 receptors) in individuals with MASLD/MASH, where hepatic biopsies were used to evaluate liver outcomes [3,5,10,11,15,22-25,44-52]
Among the six identified genes, the NOX3 gene was also detected, which was previously associated with hypertension [998]
But you are breastfeeding, and that one detail changes everything
